^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HMGB1 positive

    i
    Other names: HMGB1, High Mobility Group Box 1, High-Mobility Group (Nonhistone Chromosomal) Protein 1, Sulfoglucuronyl Carbohydrate Binding Protein, High Mobility Group Protein B1, High Mobility Group Protein 1, Amphoterin, HMG-1, High-Mobility Group Box 1, SBP-1, HMG3
    Entrez ID:
    3146
    Related biomarkers:
    Expression
    4ms
    Tumor-associated neutrophils upregulate PANoptosis to foster an immunosuppressive microenvironment of non-small cell lung cancer. (PubMed, Cancer Immunol Immunother)
    Overall, this report revealed a pro-tumoral TAN cluster with HMGB1 overexpression that potentially dampen anti-tumoral immunity and contributed to immune evasion via the GATA2/HMGB1/TIM-3 axis. Moreover, this report suggests that this specific phenotype of TAN could serve as an indicator to clinical outcomes and immunotherapy effects for NSCLC.
    Journal • IO biomarker
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • HMGB1 (High Mobility Group Box 1) • GATA2 (GATA Binding Protein 2)
    |
    HMGB1 overexpression • HMGB1 positive
    almost2years
    HMGB1 overexpression promotes a malignant phenotype and radioresistance in ESCC. (PubMed, J Cancer)
    HMGB1 overexpression promoted cell migration, proliferation, and radioresistance and mitigated cell cycle arrest at the G0/G1 phase induced by irradiation. This demonstrates that HMGB1-positive expression is correlated with unfavorable clinical outcomes, and HMGB1 overexpression may promote the malignant phenotype of ESCC cells and induce radioresistance by regulating cell cycle distribution in ESCC.
    Journal
    |
    HMGB1 (High Mobility Group Box 1) • H2AX (H2A.X Variant Histone)
    |
    HMGB1 positive
    almost2years
    SPARC: Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=3, Terminated, Duke University | Active, not recruiting --> Terminated; Poor accrual.
    Trial termination
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • CCL2 (Chemokine (C-C motif) ligand 2) • CD40 (CD40 Molecule)
    |
    PD-L1 expression • HMGB1 positive
    |
    Cabometyx (cabozantinib tablet)
    almost2years
    SPARC: Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=3, Active, not recruiting, Duke University | Recruiting --> Active, not recruiting | N=33 --> 3 | Trial completion date: Jan 2026 --> Jun 2024 | Trial primary completion date: Jan 2023 --> Jun 2021
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • CCL2 (Chemokine (C-C motif) ligand 2) • CD40 (CD40 Molecule)
    |
    PD-L1 expression • HMGB1 positive
    |
    Cabometyx (cabozantinib tablet)
    almost2years
    HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel. (PubMed, Cell Death Dis)
    This study unveils a new interaction among HMGA1, p27, and stathmin that is critical in BC cell migration. Moreover, our data suggest that taxol-based treatments may be more effective in reducing the tumour burden when tumour cells express low levels of HMGA1.
    Journal
    |
    HMGA1 (High Mobility Group AT-Hook 1) • CDKN1B (Cyclin dependent kinase inhibitor 1B)
    |
    HMGA1 overexpression • HMGB1 positive • CDKN1B expression
    |
    paclitaxel
    2years
    SPARC: Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, Duke University | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2022 --> Jan 2023
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • CCL2 (Chemokine (C-C motif) ligand 2) • CD40 (CD40 Molecule)
    |
    PD-L1 expression • HMGB1 positive
    |
    Cabometyx (cabozantinib tablet)
    over2years
    Peritumoral B cells drive proangiogenic responses in HMGB1-enriched esophageal squamous cell carcinoma. (PubMed, Angiogenesis)
    Overexpression of HMGB1 in ESCC cell lines (KYSE510 and EC18) enhanced proliferation and migration of B cells...Finally, co-injection of B cells and CM with HMGB1-overexpressing tumor cells, but not with glycyrrhizin, significantly enhanced tumor growth associated with increased microvascular density in ESCC xenograft mice model. Our results indicate that cancer-derived HMGB1 elevates angiogenesis in ESCC by shifting the balance toward proangiogenic signals in proliferating B cells.
    Journal
    |
    HMGB1 (High Mobility Group Box 1)
    |
    VEGFA expression • HMGB1 positive
    |
    mosedipimod (EC-18)
    3years
    HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer. (PubMed, Cancer Sci)
    CDK4/6 inhibitors could down-regulate the expression of HMGB1 and suppress TLR4-NF-κB pathway, in turn reverse tamoxifen resistance. These results illuminated the critical role of HMGB1 in the process of tamoxifen resistance, explained the mechanism of CDK4/6 inhibitors reversing tamoxifen resistance, and suggested the feasibility of HMGB1 serving as a potential biomarker for screening sensitive patients of CDK4/6 inhibitors.
    Clinical • Journal • IO biomarker
    |
    HMGB1 (High Mobility Group Box 1)
    |
    HR positive • HMGB1 positive
    |
    tamoxifen
    over3years
    SPARC: Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, Duke University | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2021 --> Jan 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • CCL2 (Chemokine (C-C motif) ligand 2) • CD40 (CD40 Molecule)
    |
    PD-L1 expression • HMGB1 positive
    |
    Cabometyx (cabozantinib tablet)
    almost4years
    SPARC: Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, Duke University | Suspended --> Recruiting
    Clinical • Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • CCL2 (Chemokine (C-C motif) ligand 2) • CD40 (CD40 Molecule)
    |
    PD-L1 expression • HMGB1 positive
    |
    Cabometyx (cabozantinib tablet)
    almost4years
    SPARC: Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=33, Suspended, Duke University | Recruiting --> Suspended
    Clinical • Trial suspension
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • CCL2 (Chemokine (C-C motif) ligand 2) • CD40 (CD40 Molecule)
    |
    PD-L1 expression • HMGB1 positive
    |
    Cabometyx (cabozantinib tablet)
    4years
    SPARC: Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, Duke University | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • CCL2 (Chemokine (C-C motif) ligand 2) • CD40 (CD40 Molecule)
    |
    PD-L1 expression • HMGB1 positive
    |
    Cabometyx (cabozantinib tablet)